Dr. Galsky explains results of pivotal adjuvant immunotherapy trials in urothelial cancer

Matthew Galsky, MD, discusses the discordant results of the pivotal phase 3 CheckMate-274 and IMvigor010 trials of adjuvant immunotherapy in urothelial cancer.

In an interview during the SUO 23rd Annual Meeting, Matthew Galsky, MD, discussed the pivotal phase 3 CheckMate-274 IMvigor010 trials, and the how the results of the studies yielded discordant outcomes regarding the efficacy of adjuvant immunotherapy in urothelial cancer.

Galsky is a professor of Medicine and director of Genitourinary Medical Oncology at the Icahn School of Medicine, Mount Sinai, and the co-director of the Center of Excellence for Bladder Cancer and associate director for translational research at the Tisch Cancer Institute.